As of November 30, 2024, cansinobio's H shares and A shares have not experienced changes in the number of shares. H shares are listed on the Hong Kong Stock Exchange, with a statutory share capital of 132,670,900 shares, while A shares are listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange, with a statutory share capital of 114,778,999 shares. The number of issued shares and treasury shares for both remains unchanged. Cansinobio passed an A-share repurchase plan on January 23, 2022, intended for future employee stock plans or stock-based incentives. As of November 2024, 406,098 A shares have been repurchased as treasury shares, but have not been cancelled. If not used within the legal deadline, the remaining treasury A shares will be cancelled. Within this month, cansinobio has not conducted any share repurchases or issuances, and the number of issued shares and treasury shares remains unchanged.

As of November 30, 2024, cansinobio's H shares and A shares have not experienced changes in the number of shares. H shares are listed on the Hong Kong Stock Exchange, with a statutory share capital of 132,670,900 shares, while A shares are listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange, with a statutory share capital of 114,778,999 shares. The number of issued shares and treasury shares for both remains unchanged. Cansinobio passed an A-share repurchase plan on January 23, 2022, intended for future employee stock plans or stock-based incentives. As of November 2024, 406,098 A shares have been repurchased as treasury shares, but have not been cancelled. If not used within the legal deadline, the remaining treasury A shares will be cancelled. Within this month, cansinobio has not conducted any share repurchases or issuances, and the number of issued shares and treasury shares remains unchanged.